Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioStem Technologies, Inc.BSEM · Entity 7054 | Chief Commercial Officer | September 09, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioStem Technologies, Inc.
Report date September 09, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,003 |
Reported balance
After 2026-09-09 transaction · row 1
1 source rowRow 1 · 2026-09-09 · Exercise / conversion · Acquired 500 · Balance 5,003 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,497 |
Reported balance
After 2026-09-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-09 · Exercise / conversion · Disposed 500 · Balance 4,497 F4: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F5: These restricted stock units vest in equal quarterly installments over four years from the grant date (December 9, 2024). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,519 |
Reported balance
Holding disclosure · report date 2026-09-09 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 1,519 F4: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F6: These restricted stock units vest according to the following schedule: 33% vested on February 1, 2026, the one-year anniversary of the grant date, with the remaining unites vesting in equal quarterly installments over the subsequent two year period. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 58,182 |
Reported balance
Holding disclosure · report date 2026-09-09 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 58,182 F4: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F7: These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.89 · Expires 2035-02-01 | Direct | 11,417 |
Reported balance
Holding disclosure · report date 2026-09-09 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 11,417 F1: These options vest according to the following schedule: 33% vested on February 1, 2026, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.89 · Expires 2035-10-13 | Direct | 2,427 |
Reported balance
Holding disclosure · report date 2026-09-09 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 2,427 F2: These options vest according to the following schedule: 33%% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2036-02-11 | Direct | 70,485 |
Reported balance
Holding disclosure · report date 2026-09-09 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 70,485 F3: These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest according to the following schedule: 33% vested on February 1, 2026, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
F2: These options vest according to the following schedule: 33%% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
F3: These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
F4: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F5: These restricted stock units vest in equal quarterly installments over four years from the grant date (December 9, 2024).
F6: These restricted stock units vest according to the following schedule: 33% vested on February 1, 2026, the one-year anniversary of the grant date, with the remaining unites vesting in equal quarterly installments over the subsequent two year period.
F7: These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2026 Filed Sep 11, 2026 20:15 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionRestricted Stock Units · Derivative | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-389289 · ownership.xml · derivative · entry 5 HASSETT BARRY · CIK 0002147293 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,497 Underlying: Common Stock · 500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F5 · derivative.exercise_date: These restricted stock units vest in equal quarterly installments over four years from the grant date (December 9, 2024). F5 · derivative.expiration_date: These restricted stock units vest in equal quarterly installments over four years from the grant date (December 9, 2024). Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 20:15 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-389289 · ownership.xml · nonDerivative · entry 1 HASSETT BARRY · CIK 0002147293 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,003 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.